Galapagos initiates cachexia drug Phase I Proof-of-Mechanism trial

The trial aims to evaluate the tolerability, pharmacokinetics (PK) and safety of GLPG0492 on muscle function in healthy volunteers.

Earlier, in a Phase I study in healthy volunteers, GLPG0492 demonstrated good safety and a PK profile which supports once- daily oral dosing.

Galapagos Development SVP Piet Wigerinck said this is the third time this year they initiate a clinical study designed to give insight into the potential clinical benefits of a candidate drug.

"We aim to finalize this study by the end of 2011 before further evaluating the compound in a patient population," Wigerinck said.